Zokinvy ((lonafarnib) achieves FDA approval
… Eiger BioPharmaceuticals Earns FDA Approval For Zokinvy …

Eiger Biopharmaceuticals: Zokinvy (lonafarnib) Earns FDA Approval

The first treatment for Hutchinson-Gilford Progeria Syndrome and some progeroid laminopathies

As a new therapy with no equal, Zokinvy is a go-to option where none existed before

Zokinvy is a novel, highly specialized therapy

Eiger’s market access strategy will be compact due to Zokinvy’s narrow indication and highly specialized patient care segment

The FDA recognizes the significance Zokinvy has for medical professionals and the patients they care for

Eiger BioPharmaceuticals is dedicated to the exploration and creation of new complex therapies to treat uncommon and challenging diseases

  • Lonafarnib/Ritonavir for Hepatitis Delta Virus (HDV): Phase III
  • Peginterferon Lambda for Hepatitis Delta Virus (HDV): Phase III ready
  • Avexitide for post-bariatric hypoglycemia (PBH): Phase III ready
  • Avexitide for congenital hyperinsulinism (CHI): Phase II